Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
Trial ID or NCT#
NCT00131937
Status
NOT RECRUITING
Purpose
This phase II trial is studying how well sorafenib works in treating patients with recurrent diffuse large B-cell non-Hodgkin's lymphoma. Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Official Title
A Phase II Study of Sorafenib (BAY 43-9006) in Recurrent Aggressive Non-Hodgkin's Lymphoma
Investigator(s)
Ranjana H Advani
Lymphoma specialist,
Hematologist-Oncologist
Saul A. Rosenberg, MD, Professor of Lymphoma
Contact us to find out if this trial is right for you.
Contact
Sarah Daadi
6507256456
View on ClinicalTrials.gov
